AstraZeneca, Pfizer vaccines effective against Delta COVID-19 variants-study - (Investing.com via NewsPoints Desk)

  • According to a study by Oxford University, COVID-19 vaccines developed by AstraZeneca and Pfizer-BioNTech remain broadly effective against Delta and Kappa variants of the COVID-19 causing virus, which were first identified in India, as reported by Investing.com.

  • The study, published in the journal Cell, investigated the ability of antibodies in the blood from people who were vaccinated to neutralize the Delta and Kappa variants.

  • "There is no evidence of widespread escape suggesting that the current generation of vaccines will provide protection against the B.1.617 lineage," the paper said, referring to the Delta and Kappa variants.

  • However, the researchers cautioned that the concentration of neutralising antibodies in the blood was somewhat reduced, which may lead to some breakthrough infections.

  • The researchers also analysed the possibility of reinfection in people who had previously had COVID-19. Looking at the ability of antibodies in their blood samples to neutralize the variants, the risk of reinfection with the Delta variant appeared particularly high in people previously infected by the Beta and Gamma variants that were first identified in South Africa and Brazil, respectively.

  • Meanwhile, previous infection with the Alpha, or B117, variant first detected in the UK, conferred "reasonable" cross-protection against all variants of concern. "B117 might be a candidate for new variant vaccines to provide the broadest protection," the researchers said.

To read more NewsPoints articles, click here.